Evogene (NASDAQ:EVGN) Stock Price Crosses Below 200 Day Moving Average of $5.81

Evogene Ltd. (NASDAQ:EVGN) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $5.81 and traded as low as $2.62. Evogene shares last traded at $3.07, with a volume of 114,127 shares.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EVGN. Lake Street Capital cut their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, August 23rd. StockNews.com began coverage on shares of Evogene in a research report on Tuesday. They issued a “sell” rating on the stock.

Evogene Stock Up 19.9 %

The stock has a fifty day moving average of $3.65 and a 200-day moving average of $5.81. The firm has a market capitalization of $126.53 million, a P/E ratio of -6.67 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The business had revenue of $0.91 million for the quarter. Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%.

Hedge Funds Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets increased its stake in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the period. BNP Paribas Financial Markets owned about 0.22% of Evogene worth $69,000 as of its most recent filing with the SEC. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.